IP Verse

Chugai Seiyaku Kabushiki Kaisha competitive analysis

Latest publications and patents of Chugai Seiyaku Kabushiki Kaisha New

Explore the latest publications and patents granted to Chugai Seiyaku Kabushiki Kaisha, showcasing their recent innovations and technological advancements.

Last updated on: Sep 26, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Chugai Seiyaku Kabushiki Kaisha

EP4603546
Aug 20, 2025Solid Dispersion Containing Substance To Be Dispersed, Pharmaceutical Composition Containing Same, And Production Methods ThereforPending
EP4603105
Aug 20, 2025Pharmaceutical Composition Containing Cyclic Compound Having Selective Kras Inhibitory Effect Against Hras And NrasPending
EP4596567
Aug 6, 2025Method For Removing Dibenzofulvene Or Dibenzofulvene DerivativePending
EP4408467
Aug 6, 2025Uses Of Dll3-Targeting Multispecific Antigen-Binding MoleculesPending
EP4592308
Jul 30, 2025Cyclic Compound Having Selective Kras Inhibitory Effect On Hras And NrasPending
EP4339204
Jul 30, 2025Binding Molecule Exhibiting Selective Binding For Ras(G12D) MutantPending
EP3749353
Jul 30, 2025Nemolizumab In The Treatment Of Atopic Dermatitis With Moderate To Severe ExcoriationGranted
EP3305325
Jul 30, 2025Mental Illness Therapeutic Agent Having Il-6 Inhibitor As Active IngredientGranted
EP4166133
Jul 23, 2025Composition Containing Peptide Compound And SurfactantGranted
EP3878836
Jul 23, 2025O-Substituted Serine Derivative Production MethodGranted

Latest oppositions filed by Chugai Seiyaku Kabushiki Kaisha

Explore patent oppositions filed by Chugai Seiyaku Kabushiki Kaisha against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 2, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3365368
Tgfbeta1-Binding Immunoglobulins And Use ThereofSCHOLAR ROCKFeb 16, 2024
EP2981822
Compositions And Methods For Growth Factor ModulationSCHOLAR ROCKJun 1, 2021
EP2956483
Therapeutic And Diagnostic Target For Cancer Comprising Dll3 Binding ReagentsBOEHRINGER INGELHEIMFeb 26, 2021

Latest patents of Chugai Seiyaku Kabushiki Kaisha opposed by its competitors

Explore Chugai Seiyaku Kabushiki Kaisha's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3509637
Nov 27, 2024Methods Of Using A Bispecific Antibody That Recognizes Coagulation Factor Ix And/Or Activated Coagulation Factor Ix And Coagulation Factor X And/Or Activated Coagulation Factor X4
EP3135287
Nov 20, 2024Preparation Containing Tetracyclic Compound At High Dose3
EP3702368
Nov 20, 2024Antigen-Binding Molecules That Promote Antigen Clearance1
EP3181581
Sep 25, 2024Antibodies With Modified Affinity To Fcrn That Promote Antigen Clearance1
EP3296395
Jun 19, 2024Multiple Antigen Binding Molecular Fusion, Pharmaceutical Composition, Method For Identifying Linear Epitope, And Method For Preparing Multiple Antigen Binding Molecular Fusion1
EP3202785
May 8, 2024Method For The Production Of A Glycosylated Immunoglobulin1
EP3815688
Dec 6, 2023Pharmaceutical Composition Containing Poorly-Soluble Basic Medicine2
EP2679681
Nov 15, 2023Fc Riib-Specific Fc Antibody1
EP3320773
Oct 11, 2023Non-Human Animal Having Human Cd3 Gene Substituted For Endogenous Cd3 Gene1
EP3199952
Nov 2, 2022Method For Measuring Reactivity Of Fviii2

Latest PTAB cases involving Chugai Seiyaku Kabushiki Kaisha

Discover the latest PTAB cases involving Chugai Seiyaku Kabushiki Kaisha, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 2, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Chugai Seiyaku Kabushiki Kaisha

IPR2022-01065Jun 7, 2022FRESENIUS KABI USACHUGAI SEIYAKU KABUSHIKI KAISHATerminated-Settled
IPR2022-00579Feb 21, 2022CELLTRIONCHUGAI SEIYAKU KABUSHIKI KAISHA CHUGAI PHARMACEUTICALFinal Written Decision
IPR2022-00578Feb 21, 2022CELLTRIONCHUGAI SEIYAKU KABUSHIKI KAISHA CHUGAI PHARMACEUTICALFinal Written Decision
IPR2022-00201Nov 24, 2021FRESENIUS KABI USACHUGAI SEIYAKU KABUSHIKI KAISHA CHUGAI PHARMACEUTICALTerminated-Settled
IPR2021-01542Sep 24, 2021FRESENIUS KABI USACHUGAI SEIYAKU KABUSHIKI KAISHA CHUGAI PHARMACEUTICALTerminated-Settled
IPR2021-01336Aug 18, 2021FRESENIUS KABI USACHUGAI SEIYAKU KABUSHIKI KAISHA CHUGAI PHARMACEUTICALTerminated-Settled
IPR2021-01288Aug 18, 2021FRESENIUS KABI USACHUGAI SEIYAKU KABUSHIKI KAISHA CHUGAI PHARMACEUTICALTerminated-Settled
IPR2021-01025Jun 28, 2021FRESENIUS KABI USACHUGAI SEIYAKU KABUSHIKI KAISHA CHUGAI PHARMACEUTICALTerminated-Settled
IPR2021-01024Jun 28, 2021FRESENIUS KABI USACHUGAI SEIYAKU KABUSHIKI KAISHA CHUGAI PHARMACEUTICALTerminated-Settled

Peer Comparison New

IP litigation analysis comparing Chugai Seiyaku Kabushiki Kaisha with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
CHUGAI SEIYAKU KABUSHIKI KAISHA376 - 1Defensive
GLAXO GROUP1321 - - Balanced
JAMES POOLE151 - - - Highly Aggressive
STRAWMAN331 - - - Highly Aggressive